Research note: pharmacokinetics of aditoprim in turkeys after intravenous and oral administration.
The pharmacokinetics of aditoprim, a not yet commercialized selective reversible inhibitor of dihydrofolate reductase, were determined in turkeys after intravenous (5 mg/kg BW) and oral (5.46 +/- .44 mg/kg BW) administration. The mean (+/- SD) total body clearance of 26.9 +/- 2.3 mL/min per kg BW was high when compared with that determined for other species, presumably a consequence of the higher metabolic rate of birds. Consequently, mean aditoprim elimination half-life was relatively short (3.3 +/- .2 h). As determined in mammalian species, the apparent volume of distribution at steady state was large. Aditoprim in drinking water (100 and 300 mg/L water) provided plasma concentrations between .08 and .19 micrograms/mL. Circadian rhythms with highest concentrations in the late afternoon and lowest concentrations in the morning were observed. Despite its short elimination half-life, aditoprim may still be a valuable antimicrobial for use in avian medicine pending safety, efficacy, and residue depletion studies.
Engeli
J
J
Institute of Veterinary Physiology, University of Zürich, Switzerland.
Riond
J L
JL
Wanner
M
M
D000284:Administration, Oral; D000818:Animals; D005260:Female; D005493:Folic Acid Antagonists; D007275:Injections, Intravenous / Q000662:veterinary; D014295:Trimethoprim / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D014422:Turkeys / Q000378:metabolism*
D005493:Folic Acid Antagonists; C051398:aditoprim; D014295:Trimethoprim